1. Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study.
- Author
-
Bertrand D, Cheddani L, Etienne I, François A, Hanoy M, Laurent C, Lebourg L, Le Roy F, Lelandais L, Loron MC, Godin M, and Guerrot D
- Subjects
- Adult, Aged, Case-Control Studies, Female, Follow-Up Studies, Glomerular Filtration Rate, Graft Rejection etiology, Graft Rejection pathology, Humans, Immunosuppressive Agents therapeutic use, Kidney Function Tests, Male, Middle Aged, Postoperative Complications, Prognosis, Retrospective Studies, Risk Factors, Vascular Diseases etiology, Vascular Diseases pathology, Young Adult, Abatacept therapeutic use, Graft Rejection prevention & control, Graft Survival drug effects, Kidney Failure, Chronic surgery, Kidney Transplantation adverse effects, Vascular Diseases prevention & control
- Abstract
Immunosuppression in kidney transplant recipients with decreased graft function and severe histological vascular changes can be particularly challenging. Belatacept could be a valuable option, as a rescue therapy in this context. We report a retrospective case control study comparing a CNI to belatacept switch in 17 patients with vascular damage and low eGFR to a control group of 18 matched patients with CNI continuation. Belatacept switch was performed on average 51.5 months after kidney transplantation (6.2-198 months). There was no difference between the two groups regarding eGFR at inclusion, and 3 months before inclusion. In the "CNI to belatacept switch group," mean eGFR increased significantly from 23.5 ± 6.7 mL/min/1.73m
2 on day 0, to 30.4 ± 9.1 mL/min/1.73 m2 on month 6 (p < 0.001) compared to the control group, in which no improvement was observed. These results were still significant on month 12. Two patients experienced biopsy-proven acute rejection. One was effectively treated without belatacept discontinuation. Two patients needed belatacept discontinuation for infection. In conclusion, the remplacement of CNI with belatacept in patients with decreased allograft function and vascular lesions is associated with an improvement in eGFR., (© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.)- Published
- 2017
- Full Text
- View/download PDF